Exclusive: India’s Supreme Court Reinstates Pfizer’s Sutent Patent; Orders Review For Patent Office
This article was originally published in PharmAsia News
In a new twist, India’s Supreme Court restores Pfizer’s patent for Sutent, but also removes a restraining order that had prevented Cipla from launching a generic copy.
You may also be interested in...
Prime Minister's Intervention On Patents And Data Protection Issue Sparks Fresh Row Between Indian And Multinational Drug Makers
MUMBAI - Leading multinational and India drug companies are heading for a veritable face-off over a decision of the prime minister's office to step in for a comprehensive legislative review of contentious statutes related to patent law in India
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.